Comparison of fesoterodine and tolterodine in patients with overactive bladder.
BJU Int. 2008 Jul 21. [Epub ahead of print]
Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
OBJECTIVE To compare, in a post hoc analysis of a phase III trial, the maximum recommended doses of fesoterodine (8 mg) and tolterodine (4 mg) for improving overactive bladder (OAB) symptoms and health-related quality of life (HRQoL), as fesoterodine effectively reduces OAB symptoms vs placebo....
RESULTS... Adverse events reported most commonly with active treatment included dry mouth, constipation, dry eye, dry throat, and nausea. CONCLUSIONS Both fesoterodine and tolterodine ER significantly improved OAB symptoms and HRQoL, with statistically significant advantages for fesoterodine 8 mg compared with tolterodine ER on several important endpoints.